Literature DB >> 10802757

Independent occurrence of the CHRNA4 Ser248Phe mutation in a Norwegian family with nocturnal frontal lobe epilepsy.

O K Steinlein1, J Stoodt, J Mulley, S Berkovic, I E Scheffer, E Brodtkorb.   

Abstract

PURPOSE: To describe the clinical features of a family from Northern Norway in which autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is associated with a Ser248Phe amino acid exchange in the second transmembrane domain of the neuronal nicotinic acetylcholine receptor alpha4 subunit (CHRNA4). We also tested for evidence of a de novo mutation or founder effect by comparing haplotypes with the original Australian family where the Ser248Phe mutation was first described.
METHODS: Clinical details were obtained from 19 family members. Personal interviews and genetic analysis were carried out in 17. Parts of the coding region of CHRNA4 were sequenced, and two known polymorphisms (bp555/FokI, bp594/CfoI) were typed by restriction analysis.
RESULTS: Eleven individuals had ADNFLE. The haplotypes of the mutation-carrying alleles of affected individuals from the Northern Norwegian and the Australian ADNFLE family are different. The phenotypic expressions are remarkably similar.
CONCLUSIONS: The Ser248Phe mutation occurred independently in both families. Given the rarity of the disease, this suggests that not only the position of a mutation in the coding sequence but also the type of an amino acid exchange is important for the etiology of ADNFLE. The phenotypic similarity of these two families with different genetic backgrounds suggests that the Ser248Phe mutation largely determines the phenotype, with relatively little influence of other background genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10802757     DOI: 10.1111/j.1528-1157.2000.tb00205.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Autosomal dominant nocturnal frontal lobe epilepsy--a critical overview.

Authors:  Romina Combi; Leda Dalprà; Maria Luisa Tenchini; Luigi Ferini-Strambi
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

2.  Mutational analysis of CHRNB2, CHRNA2 and CHRNA4 genes in Chinese population with autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Zhihong Chen; Lingan Wang; Chun Wang; Qian Chen; Qiongxiang Zhai; Yuxiong Guo; Yuxin Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 3.  Nocturnal frontal lobe epilepsy.

Authors:  Lino Nobili; Paola Proserpio; Romina Combi; Federica Provini; Giuseppe Plazzi; Francesca Bisulli; Laura Tassi; Paolo Tinuper
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

4.  CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  H A Phillips; I Favre; M Kirkpatrick; S M Zuberi; D Goudie; S E Heron; I E Scheffer; G R Sutherland; S F Berkovic; D Bertrand; J C Mulley
Journal:  Am J Hum Genet       Date:  2000-12-05       Impact factor: 11.025

5.  Nicotinic excitatory postsynaptic potentials in hippocampal CA1 interneurons are predominantly mediated by nicotinic receptors that contain α4 and β2 subunits.

Authors:  Karen A Bell; Hoon Shim; Ching-Kang Chen; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2011-08-25       Impact factor: 5.250

6.  A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men.

Authors:  Yan Feng; Tianhua Niu; Houxun Xing; Xin Xu; Changzhong Chen; Shaojie Peng; Lihua Wang; Nan Laird; Xiping Xu
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

Review 7.  Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology.

Authors:  Andrea Becchetti
Journal:  ISRN Biochem       Date:  2012-12-09

Review 8.  Can rodent models elucidate the pathomechanisms of genetic epilepsy?

Authors:  Motohiro Okada
Journal:  Br J Pharmacol       Date:  2021-05-12       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.